RU2008139377A - SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES - Google Patents
SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES Download PDFInfo
- Publication number
- RU2008139377A RU2008139377A RU2008139377/15A RU2008139377A RU2008139377A RU 2008139377 A RU2008139377 A RU 2008139377A RU 2008139377/15 A RU2008139377/15 A RU 2008139377/15A RU 2008139377 A RU2008139377 A RU 2008139377A RU 2008139377 A RU2008139377 A RU 2008139377A
- Authority
- RU
- Russia
- Prior art keywords
- stearic acid
- solid dosage
- dosage form
- polyvinylpyrrolidone
- salt
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract 3
- 239000007787 solid Substances 0.000 title 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract 14
- 235000021355 Stearic acid Nutrition 0.000 claims abstract 12
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract 12
- 239000007909 solid dosage form Substances 0.000 claims abstract 12
- 239000008117 stearic acid Substances 0.000 claims abstract 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims abstract 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims abstract 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000000600 sorbitol Substances 0.000 claims abstract 6
- 235000010356 sorbitol Nutrition 0.000 claims abstract 6
- 239000004475 Arginine Substances 0.000 claims abstract 4
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 claims abstract 4
- JPXZQMKKFWMMGK-KQYNXXCUSA-K IDP(3-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 JPXZQMKKFWMMGK-KQYNXXCUSA-K 0.000 claims abstract 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960004171 hydroxychloroquine Drugs 0.000 claims abstract 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960003105 metformin Drugs 0.000 claims abstract 4
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims abstract 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 239000000654 additive Substances 0.000 claims abstract 2
- 159000000007 calcium salts Chemical class 0.000 claims abstract 2
- 229960000346 gliclazide Drugs 0.000 claims abstract 2
- 239000011777 magnesium Substances 0.000 claims abstract 2
- 229910052749 magnesium Inorganic materials 0.000 claims abstract 2
- 229940069328 povidone Drugs 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims abstract 2
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1. Твердая дозированная лекарственная форма для лечения сахарного диабета, содержащая в качестве действующего вещества комбинацию терапевтически эффективных количеств метформина, рибоксин, бутадиона, аргинина, гидроксихлорохина и гликлазида в соотношении 5-40:4-30:3-20:3-20:2-10:1 и целевые добавки, в качестве которых она содержит сорбитол, поливинилпирролидон, стеариновую кислоту и/или соль стеариновой кислоты и кроскармеллозу натрия при следующем соотношении компонентов, мас.%: ! метформин 20,0-40,0 рибоксин 17,0-35,0 бутадион 7,0-20,0 аргинин 7,0-20,0 гидроксихлорохин 5,0-15,0 гликлазид 1,0-3,0 сорбитол 2,0-8,0 поливинилпирролидон 1,5-4,5 стеариновая кислота и/или соль стеариновой кислоты 0,2-1,0 кроскармеллоза натрия 0,5-2,0 ! 2. Твердая дозированная лекарственная форма по п.1, отличающаяся тем, что в качестве поливинилпирролидона она содержит, преимущественно, коллидон 25 (повидон). ! 3. Твердая дозированная лекарственная форма по п.1 или 2, отличающаяся тем, что в качестве соли стеариновой кислоты она содержит магниевую и/или кальциевую соли. ! 4. Твердая дозированная лекарственная форма по п.1, отличающаяся тем, что она выполнена в виде твердой лекарственной формы, преимущественно, в виде таблетки. ! 5. Твердая дозированная лекарственная форма по п.1, отличающаяся тем, что она выполнена в виде порошка, не содержащего сорбитол, поливинилпирролидон, стеариновую кислоту и/или соль стеариновой кислоты, кроскармеллозы натрия. 1. A solid dosage form for the treatment of diabetes mellitus containing, as an active ingredient, a combination of therapeutically effective amounts of metformin, riboxin, butadione, arginine, hydroxychloroquine and glyclazide in a ratio of 5-40: 4-30: 3-20: 3-20: 2 -10: 1 and target additives, in which it contains sorbitol, polyvinylpyrrolidone, stearic acid and / or a salt of stearic acid and croscarmellose sodium in the following ratio, wt.%:! metformin 20.0-40.0 riboxin 17.0-35.0 butadione 7.0-20.0 arginine 7.0-20.0 hydroxychloroquine 5.0-15.0 gliclazide 1.0-3.0 sorbitol 2 , 0-8.0 polyvinylpyrrolidone 1.5-4.5 stearic acid and / or stearic acid salt 0.2-1.0 croscarmellose sodium 0.5-2.0! 2. The solid dosage form according to claim 1, characterized in that as polyvinylpyrrolidone it contains mainly collidone 25 (povidone). ! 3. The solid dosage form according to claim 1 or 2, characterized in that as the salt of stearic acid, it contains magnesium and / or calcium salts. ! 4. The solid dosage form according to claim 1, characterized in that it is made in the form of a solid dosage form, mainly in the form of a tablet. ! 5. The solid dosage form according to claim 1, characterized in that it is made in the form of a powder that does not contain sorbitol, polyvinylpyrrolidone, stearic acid and / or a salt of stearic acid, croscarmellose sodium.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008139377/15A RU2008139377A (en) | 2008-10-06 | 2008-10-06 | SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008139377/15A RU2008139377A (en) | 2008-10-06 | 2008-10-06 | SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008139377A true RU2008139377A (en) | 2010-04-20 |
Family
ID=46274788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008139377/15A RU2008139377A (en) | 2008-10-06 | 2008-10-06 | SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2008139377A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2481124C1 (en) * | 2011-10-27 | 2013-05-10 | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | Pharmaceutical combination of atorvastatin and nicergolin for preventing or treating cerebrovascular disease |
-
2008
- 2008-10-06 RU RU2008139377/15A patent/RU2008139377A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2481124C1 (en) * | 2011-10-27 | 2013-05-10 | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | Pharmaceutical combination of atorvastatin and nicergolin for preventing or treating cerebrovascular disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011153403A (en) | STABILIZED COMPOSITION CONTAINING AT LEAST ONE ADRENERGIC COMPOUND | |
| RU2013136384A (en) | COMPOSITION CONTAINING SODIUM-Glucose Inhibitors 1 and 2 Inhibitors, and Methods for Their Use | |
| RU2015151938A (en) | TABLETABLE MEDICINE (4'-TRIFFORMETHYLPHENYL) AMID (Z) -2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID WITH IMPROVED STABILITY | |
| RU2020107416A (en) | A COMBINATION CONTAINING PALBOCYCLIB AND 6- (2,4-DICHLOROPHENYL) -5- [4 - [(3S) -1- (3-FLUOROPROPYL) PYRROLIDIN-3-YL] -8,9-DIHYDRO-7H-BENZO [7 ] ANNULENE-2-CARBONIC ACID AND ITS USE FOR TREATMENT OF CANCER | |
| RU2008139377A (en) | SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES | |
| RU2007119641A (en) | COMPOSITION INCLUDING ACETAMINOPHEN, CAFFEINE AND OPTIONAL ASPIRINE IN A MIXTURE WITH AN ALKALINE AGENT FOR INCREASING ABSORPTION | |
| RU2008115582A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE | |
| RU2013126056A (en) | COMPOSITION FOR TREATMENT OF INVERVATION DISORDERS (OPTIONS) | |
| RU2006116540A (en) | SOLID DOSED MEDICINAL FOR TREATMENT OF DIABETES | |
| RU2013130801A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES OF JOINT AND BONE TISSUES | |
| RU2004118448A (en) | PHARMACEUTICAL COMPOSITION WITH PROLONGED GLYCLAZIDE RELEASE | |
| RU2006142336A (en) | PHARMACEUTICAL COMPOSITION BASED ON LADASTEN | |
| RU2008114796A (en) | MULTI-COMPONENT COMBINED COMPOSITION PREVENTING ANTUBERCULOSIS ACTIVITY | |
| RU2009101126A (en) | PHARMACEUTICAL COMPOSITION WITH ANTIPSYCHOTIC ACTION | |
| RU2005110207A (en) | MUKOLITIC PHARMACEUTICAL COMPOSITION | |
| RU2008113043A (en) | PHARMACEUTICAL COMPOSITION WITH ANTI-MIRACLE ACTION | |
| RU2009142700A (en) | ANTI-INFLAMMATORY AND ANTI-ALLERGIC MEDICINE AND PHARMACEUTICAL COMPOSITION ON ITS BASIS | |
| RU2009114885A (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID ORAL DRUG FORM FOR THE TREATMENT OF DISEASES OF THE GASTROINTESTINAL TRACT | |
| RU2009134473A (en) | COMBINED TUBERCULOSIS DRUG | |
| RU2010134123A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALLERGIC DISEASES | |
| RU2013157797A (en) | PHARMACEUTICAL COMPOSITION FOR TREATING SUGAR DIABETES | |
| RU2012152225A (en) | DENTAL PENCIL WITH CALCIUM NANOSUBSTANCE GLUCONATE FOR THE TREATMENT OF DISEASES CONNECTED WITH A DEFICIENCY OF CALCIUM | |
| RU2016146653A (en) | PHARMACEUTICAL COMPOSITION BASED ON CHLORBENZOYLAMINOADAMANTHANE, INCREASING PHYSICAL PERFORMANCE IN THE CONDITIONS OF HIGH AND LOW TEMPERATURES | |
| RU2012124232A (en) | PHARMACEUTICAL COMPOSITION OF S1P RECEPTOR AGONIST FOR TREATMENT OF DEMIELINIZATION DISEASES | |
| RU2009130213A (en) | PHARMACEUTICAL ANTI-TUBERCULOSIS COMBINED COMPOSITION |